A trio of biotechs priced their IPOs on Thursday into Friday morning, setting the stage for their public trading debuts with more than $850 million

The FDA’s cancer drugs committee backs AstraZeneca’s Truqap in prostate cancer, but is unmoved by data for breast cancer candidate camizestrant.

Johnson & Johnson is scrapping two CAR-T cell programs for B cell lymphoma amid a wave of approvals in recent years for cell therapies and

Axsome’s Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer’s disease to be approved by the FDA.

The semaglutide franchise is changing up its branding as Novo Nordisk, seeing the cultural phenomenon that has become Ozempic, is retiring the Rybelsus name in